Transce3nd’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Transce3nd’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-148	Closed	-$336	–	1217
2024 Q4	$336	Buy	+148	New	+$273	﹤0.01%	1358

Other funds holding BCLI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LWM

Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Transce3nd's BCLI Position: Q1 2025 in Review

Transce3nd sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2025, closing a stake of 148 shares — an estimated $336 sold.

Transce3nd first reported a position in BCLI in Q4 2024 and held it in 1 quarter. The position peaked at $336 in Q4 2024. 32 funds tracked by Wall St. Rank hold BCLI as of Q1 2025.

Transce3nd reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2025 after selling out during the quarter.
Transce3nd sold 148 BRAINSTORM CELL THERAPUTC shares in Q1 2025, an estimated $336.
Transce3nd first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2024 and held it in 1 quarter.
Transce3nd's BRAINSTORM CELL THERAPUTC position peaked at $336 in Q4 2024.
32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2025.

Based on Transce3nd's 13F filing for Q1 2025, filed 5 May 2025.